Reuters logo
BRIEF-Allergan enters into licensing agreement with Assembly Biosciences
January 9, 2017 / 1:25 PM / a year ago

BRIEF-Allergan enters into licensing agreement with Assembly Biosciences

Jan 9 (Reuters) - Allergan Plc

* Will make upfront payment to assembly of $50 million for exclusive, worldwide rights to develop and commercialize UC, CD and IBS compounds

* Assembly will be entitled to receive success-based development and commercial milestone payments

* Assembly is also eligible to receive tiered royalties based on net sales

* Co, Assembly will share development costs through proof-of-concept (POC) studies, and Allergan will assume all post-POC development costs

* Allergan enters into licensing agreement with Assembly Biosciences to obtain worldwide rights to microbiome gastrointestinal development programs Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below